8 results
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
28 Aug 23
Current report (foreign)
4:49pm
, geopolitical, stock market and industry conditions. Accordingly, the market price of the Shares may not be sustainable at the direct arithmetic result
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
polarization of macrophages. In murine studies, Fc-MDNA413 demonstrated sustainable serum exposure at a dose that was well tolerated and inhibited tumor growth
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
22 Sep 22
Current report (foreign)
4:42pm
, and M2a polarization of macrophages. In murine studies, Fc-MDNA413 demonstrated sustainable serum exposure at a dose that was well tolerated and inhibited
SUPPL
MDNAF
Medicenna Therapeutics Corp.
10 Aug 22
Supplemental materials (foreign)
3:10pm
will generate sustainable earnings, be profitable or provide a return on investment in the future. The Corporation has not paid dividends in the past
SUPPL
MDNAF
Medicenna Therapeutics Corp.
8 Aug 22
Supplemental materials (foreign)
8:40pm
that any of its contemplated products will generate sustainable earnings, be profitable or provide a return on investment in the future
SUPPL
yb05woj6t4aw8hh 6h0
30 Dec 20
Supplemental materials (foreign)
5:28pm
F-10/A
zdjqm4 7iutzoz93t5md
28 Jul 20
Registration of securities (Canada) (amended)
5:17pm
F-10
qgjbre5f7hqouj9g7ntm
3 Jun 20
Registration of securities (Canada)
3:54pm
- Prev
- 1
- Next